Advertisement
Table 1 Main patient and tumour characteristics (n = 258)
| Characteristics | |
|---|---|
| Median age at diagnosis; years (range) | 50 (18–80) |
| Histological type of primary tumour; n (%) | |
| Ductal | 228 (88.4) |
| Lobular | 21 (8.1) |
| Other subtypes | 9 (3.5) |
| Tumour subgroup; n (%) | |
| ER-positive | 184 (71.32) |
| PR-positive | 122 (47.29) |
| HR-positive | 189 (73.3) |
| HER2-positive | 26 (10.2) |
| Triple negative | 58 (22.5) |
| ECOG performance status (%) | |
| 0 | 73 (28.3) |
| 1 | 133 (51.6) |
| 2 | 46 (17.8) |
| 3 | 6 (2.3) |
| Previous chemotherapy for (neo) adjuvant/advanced disease | |
| Anthracyclines; n (%) | 244 (94.6) |
| Taxanes; n (%) | 253 (98.1) |
| Capecitabine; n (%) | 234 (90.7) |
| Median prior lines of chemotherapy in the metastatic setting (range) | 4 (1–9) |
| Best response under previous taxane therapy; n (%) | |
| Complete response | 20 (7.8) |
| Partial response | 112 (43.8) |
| Stable disease | 78 (30.5) |
| Progressive disease | 33 (12.9) |
| Not evaluable | 13 (5.1) |
| Missing | 2 |
| Hormonal therapy | |
| Prior hormonal therapy (HR+ tumours; n [%]) | 184 (97.3) |
| Metastatic sites; n (%) | |
| Visceral metastases | 223 (86.4) |
| Liver | 174 (67.4) |
| Node | 118 (45.7) |
| Lung | 98 (38.0) |
| Brain | 41 (15.9) |
| Serous | 55 (21.3) |
| Skin | 31 (12.0) |
| Bone | 176 (68.2) |
| Other sites | 26 (10.1) |
